ofatumumab   Click here for help

GtoPdb Ligand ID: 6778

Synonyms: Arzerra® | GSK 1841157 | GSK1841157 | humax-CD20 | Kesimpta® (subcutaneous) | OMB-157 | OMB157
Approved drug Immunopharmacology Ligand
ofatumumab is an approved drug (FDA (2009), EMA (2010))
Compound class: Antibody
Comment: Ofatumumab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ofatumumab

Immunopharmacology Comments
Binding of ofatumumab to the membrane-proximal epitope of CD20 induces recruitment and activation of the complement pathway at the cell surface. This leads to complement-dependent cytotoxicity which results in lysis of tumour cells.
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
 Approved drug for some CLL patients.